Table 1.
Baseline characteristics of all patients
| Characteristic | Total | High SIRI (≥ 0.89) | Low SIRI (< 0.89) | p-value |
|---|---|---|---|---|
| Sex | ||||
| Male | 69 (55.6) | 34 (50.0) | 35 (62.5) | 0.204 |
| Female | 55 (44.4) | 34 (50.0) | 21 (37.5) | |
| Age (yr) | ||||
| ≤ 65 | 72 (58.1) | 37 (54.4) | 35 (62.5) | 0.465 |
| > 65 | 52 (41.9) | 31 (45.6) | 21 (37.5) | |
| Jaundice | ||||
| No | 104 (83.9) | 56 (82.4) | 48 (85.7) | 0.635 |
| Yes | 20 (16.1) | 12 (17.6) | 8 (14.3) | |
| Fever | ||||
| No | 112 (90.3) | 58 (85.3) | 54 (96.4) | 0.064 |
| Yes | 12 (9.7) | 10 (14.7) | 2 (3.6) | |
| Fatigue | ||||
| No | 115 (92.7) | 61 (89.7) | 54 (96.4) | 0.182 |
| Yes | 9 (7.3) | 7 (10.3) | 2 (3.6) | |
| Weight loss | ||||
| No | 78 (62.9) | 41 (60.3) | 37 (66.1) | 0.577 |
| Yes | 46 (37.1) | 27 (39.7) | 19 (33.9) | |
| Gallstone | ||||
| No | 69 (55.6) | 43 (63.2) | 26 (46.4) | 0.071 |
| Yes | 55 (44.4) | 25 (36.8) | 30 (53.6) | |
| Hypertension | ||||
| No | 86 (69.4) | 52 (76.5) | 34 (60.7) | 0.078 |
| Yes | 38 (30.6) | 16 (23.5) | 22 (39.3) | |
| Diabetes | ||||
| No | 97 (78.2) | 54 (79.4) | 43 (76.8) | 0.828 |
| Yes | 27 (21.8) | 14 (20.6) | 13 (23.2) | |
| Combined inflammatory status | ||||
| No | 120 (96.8) | 65 (95.6) | 55 (98.2) | 0.626 |
| Yes | 4 (3.2) | 3 (4.4) | 1 (1.8) | |
| Preoperative antibiotics usage | ||||
| No | 116 (93.5) | 62 (91.2) | 54 (96.4) | 0.292 |
| Yes | 8 (6.5) | 6 (8.8) | 2 (3.6) | |
| BMI (kg/m2) | ||||
| ≥ 24 | 56 (45.2) | 29 (42.6) | 27 (48.2) | 0.589 |
| < 24 | 68 (54.8) | 39 (57.4) | 29 (51.8) | |
| CA19-9 (U/mL) | ||||
| > 40 | 62 (50.0) | 41 (60.3) | 21 (37.5) | 0.019 |
| ≥ 40 | 62 (50.0) | 27 (39.7) | 35 (62.5) | |
| Maximum tumor size (cm) | 3.00 (1.77-4.85) | 3.00 (1.87-5.00) | 2.60 (1.60-4.50) | 0.341 |
| Histologic type | ||||
| Adenocarcinoma | 119 (96.0) | 64 (94.1) | 55 (98.2) | 0.377 |
| Other | 5 (4.0) | 4 (5.9) | 1 (1.8) | |
| Resection (R0) | ||||
| No | 43 (34.7) | 33 (48.5) | 10 (17.9) | 0.001 |
| Yes | 81 (65.3) | 35 (51.5) | 46 (82.1) | |
| Radical surgery | ||||
| No | 54 (43.5) | 39 (57.4) | 15 (26.8) | 0.001 |
| Yes | 70 (56.5) | 29 (42.6) | 41 (73.2) | |
| Tumor differentiation | ||||
| G1 | 28 (22.6) | 12 (17.6) | 16 (28.6) | 0.371 |
| G2 | 44 (35.5) | 24 (35.3) | 20 (35.7) | |
| G3 | 37 (29.8) | 24 (35.3) | 13 (23.2) | |
| Gx | 15 (12.1) | 8 (11.8) | 7 (12.5) | |
| TNM stage | ||||
| 0 | 4 (3.2) | 2 (2.9) | 2 (3.6) | 0.024 |
| I | 11 (8.9) | 2 (2.9) | 9 (16.1) | |
| IIA | 12 (9.7) | 5 (7.4) | 7 (12.5) | |
| IIB | 2 (1.6) | 1 (1.5) | 1 (1.8) | |
| IIIA | 39 (31.5) | 20 (29.4) | 19 (33.9) | |
| IIIB | 41 (33.1) | 26 (38.2) | 15 (26.8) | |
| IVA | 4 (3.2) | 2 (2.9) | 2 (3.6) | |
| IVB | 11 (8.9) | 10 (14.7) | 1 (1.8) | |
| Follow-up (mo) | 20.00 (7.75-34.00) | 12.50 (6.00-29.50) | 27.00 (16.25-48.25) | 0.009 |
| Death | ||||
| No | 45 (36.3) | 17 (25.0) | 28 (50.0) | 0.005 |
| Yes | 79 (63.7) | 51 (75.0) | 28 (50.0) |
Values are presented as number (%) or median (range). SIRI, systemic inflammation response index; BMI, body mass index; CA19-9, carbohydrate antigen 19-9; TNM, tumor-node-metastasis.